Get the Daily Brief
Latest Biotech News
Novartis pays $2 billion upfront for Synnovation PI3Kα asset — Deal secures next‑gen breast cancer candidate
Novartis announced a deal to acquire a Synnovation unit for $2 billion up front to secure SNV4818, a mutant‑selective PI3Kα inhibitor intended for HR+/HER2‑ breast cancer. The acquisition gives...
Earendil Labs raises $787M to scale AI‑driven biologics R&D — Backing from Dimension, Luminous, Sanofi
AI‑powered biotech Earendil Labs secured $787 million in private financing to accelerate a sprawling biologics pipeline and build an R&D organization across the U.S. and China. Investors named in...
Abbott closes Exact Sciences deal Monday — $23B buy adds cancer‑screening and diagnostics assets
Abbott confirmed that its $23 billion acquisition of Exact Sciences has cleared regulatory hurdles and is set to close, bringing Cologuard, Oncotype DX and other cancer‑screening and diagnostic...
FDA insists on sham‑surgery control for uniQure’s Huntington’s gene therapy — Regulators question external controls
The US Food and Drug Administration told uniQure it requires a prospective, randomized, double‑blind, sham surgery‑controlled study to support approval of AMT‑130, the AAV‑based Huntington’s...
Roche halts development of experimental SMA drug emugrobart — Patient letter cites insufficient benefit
Roche informed European patients that it will discontinue development of emugrobart after studies failed to show consistent improvements in muscle growth and motor function. The decision affects a...
Tumor whole‑genome sequencing shows real‑world clinical utility — 888‑patient Nature Medicine study
A Nature Medicine report on 888 patients demonstrated that routine paired tumor‑normal whole‑genome sequencing (WGS) is feasible in clinical oncology and yields actionable results. WGS succeeded...
Lab‑grown esophagus functions in growing pigs — GOSH/UCL report advances pediatric regeneration
Researchers from Great Ormond Street Hospital and University College London reported in Nature Biotechnology the successful engineering, implantation and functional integration of an autologous,...
Startup pays women for menstrual stem‑cell donations — Muse Bio targets regenerative and fertility markets
SF startup Muse Bio is recruiting menstrual blood donors with $40 payments to build a biobank of menstrual‑derived stem cells (MenSCs) for cosmetics, regenerative medicine and fertility...
FDA expands Rhythm’s Imcivree to acquired hypothalamic obesity — First drug for the rare condition
The FDA widened the label for Rhythm Pharmaceuticals’ Imcivree (setmelanotide) to include acquired hypothalamic obesity in adults and children aged four and older. Clinical trials showed Imcivree...
AI clinical decision support improves stroke care and outcomes — Cluster‑randomized BMJ trial in China
A cluster‑randomized clinical trial published in The BMJ found that an AI‑driven clinical decision support system (CDSS) significantly improved care quality and long‑term outcomes in acute...
Novartis pays $2B for PI3Kα inhibitor: Bolsters breast‑cancer arsenal
Novartis agreed to acquire a Synnovation unit and pay $2 billion upfront to secure SNV4818, a next‑generation PI3Kα inhibitor that selectively targets mutant PI3Kα. The asset, in early clinical...
Earendil raises $787M: AI biologics developer scales pipeline
Earendil Labs closed a $787 million financing to advance an AI‑driven biologics pipeline spanning autoimmune and oncology programs. The round included Dimension, Luminous Ventures and Sanofi among...
Abbott to close $23B Exact Sciences deal – Expands diagnostics footprint
Abbott prepared to close its $23 billion acquisition of Exact Sciences after securing regulatory clearances. The deal brings Cologuard, Oncotype DX, Oncodetect and multi‑cancer early detection...
Big pharma shutters muscle‑growth bets – Roche, Genentech scale back programs
Two major drugmakers halted late‑stage muscle‑growth and muscle‑preserving programs after trial data failed to show consistent benefit. Roche announced it would stop development of emugrobart...
FDA asks for sham‑surgery control in uniQure Huntington’s trial – Ethics and timing at stake
The U.S. FDA told uniQure to conduct a prospective, randomized, double‑blind, sham surgery‑controlled study to support marketing of AMT‑130, an AAV‑based gene‑editing therapy for Huntington’s...
Tumor whole‑genome sequencing: actionable biomarkers found in 73% of cases
A real‑world study of paired tumor‑normal whole‑genome sequencing (WGS) in 888 solid‑tumor patients demonstrated high technical success (89%), a median six‑day turnaround, and identified...
Scaling cell therapy: automation and light‑gated CARs aim to expand access
Two developments signal parallel moves to industrialize and better control cell therapies. Cellares executives discussed using automation, closed manufacturing systems and global networks to...
Generalist biological AI: Nature Biotechnology frames cross‑domain vision
Nature Biotechnology published a review outlining a vision for generalist biological AI—models that can perform diverse tasks across biological domains. The paper evaluates promises and pitfalls,...
ACIP turmoil: claims of disbanding follow judge’s injunction
The Advisory Committee on Immunization Practices (ACIP) has been embroiled in upheaval after a federal judge issued a temporary injunction questioning the appointment process of newly installed...
Lab‑grown esophagus restores swallowing in pig models – Leap for pediatric repair
Researchers at Great Ormond Street Hospital and UCL reported functional integration of an autologous engineered esophagus in a growing large‑animal model. Teams decellularized donor porcine...